0.177

4.84% -0.009

Pre-market: .19 0.013 +7.34%

Mustang Bio Inc (MBIO)

Overview News Price History Financials Why MBIO Down? Discussions Forecast Stock Split

Mustang Bio Inc stock is traded at $0.177, with a volume of 2.48M. It is down -4.84% in the last 24 hours and down -11.28% over the past month. Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Previous Close:

$0.186

Open:

$0.19

24h Volume:

2.48M

Relative Volume:

1.41

Market Cap:

$8.78M

Revenue:

Net Income/Loss:

$-40.10M

P/E Ratio:

-0.0187

EPS:

-9.46

Net Cash Flow:

$-36.99M

1W Performance:

+5.92%

1M Performance:

-11.28%

6M Performance:

-62.58%

1Y Performance:

-86.89%

1-Day Range:

$0.162

$0.1979

1-Week Range:

$0.162

$0.1979

52-Week Range:

$0.1281

$1.53

Mustang Bio Inc Stock (MBIO) Company Profile

Name

Mustang Bio Inc

Sector

Healthcare (1173)

Industry

Biotechnology (670)

Phone

(781) 652-4500

Address

377 PLANTATION STREET, WORCESTER, NY

Employee

Twitter

@Mustang_Bio

Next Earnings Date

2024-11-12

Latest SEC Filings

MBIO's Discussions on Twitter

Compare MBIO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MBIO Mustang Bio Inc	0.177	8.78M	0	-40.10M	-36.99M	-4.40
VRTX Vertex Pharmaceuticals Inc	402.70	103.71B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	712.33	78.28B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	615.00	36.77B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	235.31	30.35B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.95	27.32B	3.30B	-501.07M	1.03B	-2.1146

Mustang Bio Inc Stock (MBIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-18-21	Initiated	BTIG Research	Buy
Oct-02-20	Initiated	B. Riley FBR	Buy
Nov-20-19	Initiated	Cantor Fitzgerald	Overweight
Aug-13-19	Initiated	H.C. Wainwright	Buy
Jun-21-19	Initiated	Cantor Fitzgerald	Overweight
Dec-21-17	Initiated	Oppenheimer	Outperform

View All

Mustang Bio Inc Stock (MBIO) Latest News

Dec 27, 2024

Likelihood of Approval and Phase Transition Success Rate ModelMB-108 in Recurrent Malignant Glioma - GlobalData

Dec 04, 2024

Nov 29, 2024

Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve

Nov 29, 2024

Nov 17, 2024

Mustang Bio faces delisting, appoints new interim CFO - Investing.com

Nov 17, 2024

Nov 15, 2024

Mustang Bio's Interim CFO Resigns After 10 Months - MarketWatch

Nov 15, 2024

Mustang Bio Faces Nasdaq Delisting and Leadership Changes - TipRanks

Nov 15, 2024

Mustang Bio, Inc. Announces CFO Changes - Marketscreener.com

Nov 15, 2024

ARMISTICE CAPITAL, LLC Acquires New Stake in Mustang Bio Inc - GuruFocus.com

Nov 15, 2024

Fortress Biotech Inc. (FBIOP) Quarterly 10-Q Report - Quartzy

Nov 15, 2024

Nov 12, 2024

Mustang Bio gets extension for Nasdaq compliance By Investing.com - Investing.com South Africa

Nov 12, 2024

Crude Oil Brent (F) (QAX25) Quote - The Globe and Mail

Nov 12, 2024

Mustang Bio gets extension for Nasdaq compliance - Investing.com

Nov 12, 2024

Mustang Bio Receives Positive Listing Determination from Nasdaq - The Manila Times

Nov 12, 2024

Mustang Bio Secures Critical Nasdaq Extension, Faces January 2025 Deadline for $1 Compliance | MBIO Stock News - StockTitan

Nov 12, 2024

Nov 10, 2024

Virus Therapy Gets Orphan Drug Designation for Glioma Treatment - www.oncnursingnews.com/

Nov 10, 2024

Nov 08, 2024